Logo image of RUBY

RUBIUS THERAPEUTICS INC (RUBY) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:RUBY - US78116T1034 - Common Stock

0.083 USD
-0.04 (-33.55%)
Last: 3/6/2023, 8:00:03 PM
0.0899 USD
+0.01 (+8.31%)
After Hours: 3/6/2023, 8:00:03 PM
Buy % Consensus

46

ChartMill assigns a Buy % Consensus number of 46% to RUBY. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 1.02. This target is 1128.92% above the current price.
RUBY was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about RUBY.
In the previous month the buy percentage consensus was at a similar level.
RUBY was analyzed by 7 analysts. More opinions would make the average more meaningful.

Related screens

RUBY Historical Analyst RatingsRUBY Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -54 -49 -44 -39 -34 -29 -24 -19 -14 -9 -4 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 0.081.011.021.021.05 - 1,116.87% 1,128.92% 1,128.92% 1,165.06%

Related screens

RUBY Current Analyst RatingRUBY Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades
Date Firm Action Rating
2022-09-13 Guggenheim Downgrade Buy -> Neutral
2022-09-09 Morgan Stanley Maintains Equal-Weight
2022-08-09 SVB Leerink Maintains Market Perform
2022-05-11 Morgan Stanley Maintains Equal-Weight
2022-05-11 HC Wainwright & Co. Maintains Buy
2022-05-10 SVB Leerink Maintains Market Perform
2022-04-11 Guggenheim Maintains Buy
2022-04-11 SVB Leerink Maintains Market Perform
2022-04-11 Morgan Stanley Maintains Equal-Weight
2022-04-11 HC Wainwright & Co. Maintains Buy
2022-02-25 SVB Leerink Maintains Market Perform
2021-11-09 SVB Leerink Maintains Market Perform
2021-05-18 Morgan Stanley Maintains Equal-Weight
2021-04-19 Morgan Stanley Maintains Equal-Weight
2021-03-15 SVB Leerink Maintains Market Perform
2021-03-15 HC Wainwright & Co. Maintains Buy
2021-02-23 SVB Leerink Maintains Market Perform

RUBIUS THERAPEUTICS INC / RUBY FAQ

What is the average price target for RUBIUS THERAPEUTICS INC (RUBY) stock?

7 analysts have analysed RUBY and the average price target is 1.02 USD. This implies a price increase of 1128.92% is expected in the next year compared to the current price of 0.083.


What is the consensus rating for RUBY stock?

The consensus rating for RUBIUS THERAPEUTICS INC (RUBY) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.